|
rs113488022
|
|
Colorectal Carcinoma
|
T |
0.900 |
CausalMutation
|
CLINVAR |
|
|
|
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Prognostic value of BRAF mutations in localized cutaneous melanoma.
|
24388723 |
2014 |
|
rs113488022
|
|
Papillary thyroid carcinoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
|
|
|
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
|
24508103 |
2014 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
|
26678033 |
2016 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
|
24576830 |
2014 |
|
rs113488022
|
|
Gastrointestinal Stromal Tumors
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.
|
20818844 |
2010 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
|
23614898 |
2013 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAF(V600E) mutation-positive melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m(2) intravenously every 3 weeks).
|
22735384 |
2012 |
|
rs113488022
|
|
Non-Small Cell Lung Carcinoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Mutations of the BRAF gene in human cancer.
|
12068308 |
2002 |
|
rs113488022
|
|
Gastrointestinal Stromal Tumors
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Inhibition of mutated, activated BRAF in metastatic melanoma.
|
20818844 |
2010 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Determinants of BRAF mutations in primary melanomas.
|
14679157 |
2003 |
|
rs113488022
|
|
Gastrointestinal Stromal Tumors
|
T |
0.800 |
CausalMutation
|
CLINVAR |
We report prolonged antitumor activity in the first patient with V600E BRAF-mutated GIST who was treated with a BRAF inhibitor.
|
23470635 |
2013 |
|
rs113488022
|
|
Gastrointestinal Stromal Tumors
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
|
21639808 |
2011 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Here, CDK2/4 inhibition statistically significantly augmented the effects of BRAF(V600E)- or MEK-inhibitors on melanoma cell viability in vitro and growth in athymic nude Foxn1 ( nu ) mice (P = .03 when mean tumor volume at day 13 was compared for BRAF(V600E) inhibitor vs BRAF(V600E) inhibitor plus CDK2/4 inhibition; P = .02 when mean tumor volume was compared for MEK inhibitor vs MEK inhibitor plus CDK2/4 inhibition; P values were calculated by a two-sided Welch t test; n = 4-8 mice per group).
|
22997239 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
|
22805292 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Improved survival with MEK inhibition in BRAF-mutated melanoma.
|
22663011 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
|
23020132 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.
|
23031422 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
|
23918947 |
2013 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
|
21156289 |
2010 |
|
rs113488022
|
|
Gastrointestinal Stromal Tumors
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
|
22608338 |
2012 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
|
20630094 |
2010 |
|
rs113488022
|
|
melanoma
|
T |
0.800 |
CausalMutation
|
CLINVAR |
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy.
|
24586605 |
2014 |